![](https://endpts.com/wp-content/uploads/2024/06/Sarah-Boyce.jpg)
Sarah Boyce, Avidity Biosciences CEO
Avidity’s early-phase data for rare muscle disease drug spur registrational plans
Avidity Biosciences’ antibody oligonucleotide conjugate has shown signs of efficacy in an early-stage test in patients with a rare muscle-wasting disease.
Just last month, Leerink …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.